Nabriva Therapeutics plc's latest marketcap:
As of 06/05/2025, Nabriva Therapeutics plc's market capitalization has reached $323. According to our data, Nabriva Therapeutics plc is the 49220th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 323 |
| Revenue (ttm) | 29.56 M |
| Net Income (ttm) | -55,054,000 |
| Shares Out | 3.23 M |
| EPS (ttm) | -17.9 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 03/28/2025 |
Nabriva Therapeutics plc's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/05/2025 | $323 | 10666.67% |
| 12/30/2024 | $3 | 0% |
| 12/29/2023 | $3 | -100% |
| 12/30/2022 | $5.79 M | -82.95% |
| 12/31/2021 | $33.97 M | -33.41% |
| 12/31/2020 | $51.01 M |
Company Profile
About Nabriva Therapeutics plc
Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing novel anti-infective agents for serious infections. Headquartered in Dublin, Ireland, the company was incorporated in 2005 and originally known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.
Key Products & Development Pipeline
- SIVEXTRO – An oxazolidinone-class antibacterial for treating acute bacterial skin and skin structure infections (ABSSSI).
- XENLETA – A semi-synthetic pleuromutilin antibiotic available in oral and IV formulations, currently in Phase I trials for pediatric infections, sexually transmitted infections, cystic fibrosis, and other serious conditions.
- CONTEPO – An epoxide antibiotic in Phase I trials for complicated urinary tract infections and peri-operative prophylaxis.
Therapeutic Focus Areas
Nabriva's research targets a range of severe infections, including:
- Ventilator-associated bacterial pneumonia
- Hospital-acquired bacterial pneumonia
- Complicated intra-abdominal infections
- Osteomyelitis and prosthetic joint infections
Frequently Asked Questions
-
What is Nabriva Therapeutics plc's (OTC-NBRVF) current market cap?As of 06/05/2025, Nabriva Therapeutics plc (including the parent company, if applicable) has an estimated market capitalization of $323 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Nabriva Therapeutics plc (OTC-NBRVF) rank globally by market cap?Nabriva Therapeutics plc global market capitalization ranking is approximately 49220 as of 06/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.